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TuberculosisIn this study we assessed ﬁrst-line anti-tuberculosis drug resistance and the genotypic distribution of
Mycobacterium tuberculosis complex (MTBC) isolates that had been collected from consecutive new tuber-
culosis patients enrolled in two clinical trials conducted in Guinea between 2005 and 2010. Among the
total 359 MTBC strains that were analyzed in this study, 22.8% were resistant to at least one of the ﬁrst
line anti-tuberculosis drugs, including 2.5% multidrug resistance and 17.5% isoniazid resistance, with or
without other drugs. In addition, further characterization of isolates from a subset of the two trials
(n = 184) revealed a total of 80 different spoligotype patterns, 29 ‘‘orphan’’ and 51 shared patterns. We
identiﬁed the six major MTBC lineages of human relevance, with predominance of the Euro-American lin-
eage. In total, 132 (71.7%) of the strains were genotypically clustered, and further analysis (using the
DESTUS model) suggesting signiﬁcantly faster spread of LAM10_CAM family (p = 0.00016). In conclusion,
our ﬁndings provide a ﬁrst insight into drug resistance and the population structure of the MTBC in
Guinea, with relevance for public health scientists in tuberculosis control programs.
 2015 Published by Elsevier B.V.1. Introduction
According to the World Health Organization (WHO),
tuberculosis (TB) is among the most wide-spread global public
health problems, and its implication for health and economy is
increasingly recognized (Lienhardt et al., 2012; WHO, 2014a,b).Mycobacterium tuberculosis and Mycobacterium africanum are the
major pathogenic species of the M. tuberculosis complex (MTBC)
in humans and remain one of the leading causes of adult deaths
due to a bacterial infection, particularly in sub-Saharan African
countries (Corbett et al., 2006; de Jong et al., 2010a,b). As the
worldwide emergence of multidrug-resistant strains has become
one of the greatest public health concerns (Lienhardt et al.,
2012), understanding the genetic backgrounds of circulating
drug-resistant strains is crucial, as observed from different studies
elsewhere (Gagneux et al., 2006).
Few West African countries have conducted drug-resistance
surveys and epidemiological studies on endemic M. tuberculosis
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et al., 2011; Traore et al., 2012), and the majority of countries in
this region are still lacking such important information (WHO,
2014a,b). Guinea faces great challenges in controlling both ende-
mic and epidemic infectious diseases, such as the recent Ebola out-
break. In 2013, a TB prevalence of 244/100,000 and TB incidence
rate of 177/100,000 was reported (WHO, 2014a,b), but no data
on genetic diversity or drug-resistance of the prevalent MTBC
strains are available up to date. Hence, we took advantage of two
clinical trials recently conducted in Guinea to type the collected
MTBC isolates and estimate the genetic diversity of the MTBC in
the country. Obtaining a ﬁrst insight into the genotypes of MTBC,
we were not only able to estimate the prevalence of drug resis-
tance among new cases in Guinea but also to describe an associa-
tion of certain mycobacterial families with drug-resistance.2. Materials and methods
2.1. Patients
This study was carried out on baseline isolates from new cases
of pulmonary TB patients in Guinea recruited in 2 different clinical
trials in the capital Conakry: the Oﬂotub Study (registration
number = NCT00216385) (Merle et al., 2012, 2014) and the Study
C (registration number = NCT00216333) (Lienhardt et al., 2011).
A sub-set of isolates had been stored at 80 C at the Institute of
Tropical Medicine (ITM), Belgium. Both studies recruited consecu-
tive adult smear positive patients without prior history of TB treat-
ment (in the Oﬂotub study, patients with prior treatment more
than 3 years ago were also eligible).2.2. Drug-susceptibility testing (DST)
For both clinical trials, DST was conducted ﬁrst in the national
TB laboratory in Conakry (CHU Ignace Deen). For quality control
(QC), in Study C, all isolates were sent to ITM in Antwerp, and in
the Oﬂotub study, any rifampicin resistant isolate and every 6th
rifampicin sensitive isolate were sent to Antwerp. In both CHU
Ignace Deen and ITM laboratories, phenotypic DST was performed
on Löwenstein–Jensen (LJ) slopes using the proportion method
(Canetti et al., 1969). Speciﬁcally, isolates were inoculated on
antibiotic-containing LJ slopes (rifampicin (RMP) 40 lg/ml, isoni-
azid (INH) 0.2 lg/ml, ethambutol (EMB) 2 lg/ml and streptomycin
(SM) 4 lg/ml), incubated at 37 C, and monitored for growth at 4
and 6 weeks. The concordance between DST results in Conakry
and ITM on the subset of isolates tested in both places in the
Oﬂotub study met international standards (Laszlo et al., 2002;
WHO, 2009), with 97% each for rifampicin and isoniazid, 100%
for ethambutol, and 92% for streptomycin. The complete Conakry
results were used for the analysis on drug resistance, to avoid bias
in the prevalence estimates.2.3. DNA extraction and spoligotyping
Of the isolates included in the present study, we identiﬁed 184
strains from the two trials; 64 strains from Study C and 120 from
Oﬂotub (Lienhardt et al., 2011; Merle et al., 2012, 2014), available
at ITM for genotyping. DNA extraction was done by resuspending a
loop-full of the stored isolate in TE buffer and boiling the mixture
for 5 min. The obtained boiled lysate was subsequently spoligo-
typed, as described elsewhere (Kamerbeek et al., 1997). The results
were recorded as the presence or absence of spacers using a binary
code (Kamerbeek et al., 1997; Dale et al., 2001).2.4. Genotype database comparison and analysis
The genotyping results were compared to the international
spoligotyping (SITVIT) database of the Pasteur Institute of
Guadeloupe (http://www.pasteur-guadeloupe.fr:8081/SITVITDemo)
(Brudey et al., 2006), and the newly revised publicly available
international multimarker database (SITVITWEB) (Demay et al.,
2012). A SIT (spoligotype international type) was assigned when
two or more patient isolates in the database shared the identical
spoligotype-patterns, while spoligotype-patterns that had not
been described before were deﬁned as ‘‘orphan’’. To assign
mycobacterial lineages and families to the genotyped isolates,
spoligotypes were analyzed using TBlineage (http://tbinsight.cs.
rpi.edu/about_tb_lineage.html) and Spotclust (http://tbinsight.cs.
rpi.edu/run_spotclust.html), respectively. Lineages and families
were deﬁned according to signatures provided in SpolDB4 and
SITVITWEB (Brudey et al., 2006; Demay et al., 2012) and also based
on earlier reports (Gagneux and Small, 2007). To detect emerging
strains of tuberculosis using Spoligotyping (DESTUS) the
spolTools homepage (http://www.emi.unsw.edu.au/spolTools/)
was used and manually clustered spoligotypes were analyzed with
the default settings. The quantitative DESTUS model considers the
mutation rate underlying each spoligotype, to detect genotypes
that are spreading faster than the background population of spolig-
otypes (Tanaka and Francis, 2006; Tang et al., 2008).
2.5. Statistical analysis
Statistical analysis was performed using SPSS Statistic 17 (SPSS
Inc., USA). Proportions of drug susceptibility test proﬁles for both
MTBC strains were compared using Chi-Square analysis. The two
sided Pearson’s Chi-Square test was used to assess associations of
drug-resistance proﬁles with spoligotype families. Furthermore,
an association of ﬁrst-line anti-tuberculosis drug resistance pro-
ﬁles with MTBC genotypes was estimated and expressed as the
odds ratio (OR) and 95% conﬁdence interval (95% CI). A p-value
of less than 0.05 was considered statistically signiﬁcant.
2.6. Ethical considerations
All patients enrolled in these clinical studies had provided
informed consent and studies were approved by the Guinean
Ethical committee. Permission to perform this sub-study was
obtained from the Institutional Research Board of the Institute of
Tropical Medicine, Belgium. No patient personal identiﬁers were
used in this study.3. Results
3.1. Drug susceptibility proﬁles
A total of 359 MTBC isolates were identiﬁed, 222 isolates from
Oﬂotub (Merle et al., 2012, 2014) collected within the period
2005–2010, and 137 from Study C (Lienhardt et al., 2011) between
2005 and 2006. Among the 222 isolates from Oﬂotub that had been
analyzed in Guinea, 171 (77%) isolates were pan-susceptible to all
ﬁrst line anti-TB drugs; 51 (23%) isolates were resistant to at least
one of the drugs, including 40 (18%) isolates with INH resistance,
whether associated or not with resistance to other drugs, and 4
(1.8%) with resistance to both RMP and INH. Isolates from Study
C included 106 (77.4%) pan-susceptible isolates and 31 (22.6%)
with resistance to at least one of the drugs, including 5 (3.6%)
MDR and 23 (16.8%) with any INH resistance (Table 1). Overall,
among new TB patients in Guinea between 2005 and 2010, the
MDR prevalence was 2.5% and 17.5% had any INH resistance.
Table 1
Prevalence of resistance among baseline M. tuberculosis complex strains of the Study C and Oﬂotub clinical trials.
Source (clinical trial) Pan-susceptible n (%) Resistance proﬁle n (%) Total
INHa SMa RMPa PDRb MDRc
Study-C 106 (77.4) 6 (4.4) 6 (4.4) 2 (1.5) 12 (8.8) 5 (3.6) 137
Oﬂotub 171 (77) 4 (1.8) 11 (5) 0 32 (14) 4 (1.8) 222
Total 277 (77.2) 10 (2.8) 17 (4.7) 2 (0.6) 44 (12.3) 9 (2.5) 359
INH = isoniazid; RMP = rifampicin; SM = streptomycin;
a Monoresistance (resistance to one ﬁrst-line anti-TB drug only) (WHO, 2014a,b).
b PDR = polydrug resistance (resistance to more than one ﬁrst-line anti-TB drug, other than both isoniazid and rifampicin (drug-resistant tuberculosis other than MDR-TB))
(WHO, 2014a,b).
c MDR = multidrug resistance (resistance to at least both isoniazid and rifampicin) (WHO, 2014a,b).
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Among the genotyped isolates (n = 184) in this study were 50
strains from 2005, 102 from 2006, 14 from 2008 and 18 from
2010 (Lienhardt et al., 2011; Merle et al., 2012). The results
revealed a total of 80 different patterns, including 29 ‘orphan’
spoligotypes and 51 different spoligotype patterns that had already
been described before (Table S1). Of the total 184 isolates, 145
(78.8%) belonged to the Euro-American (Lineage 4), 20 (10.9%) to
Indo-Oceanic (Lineage 1), 8 (4.3%) to the East Asian (Beijing,
Lineage 2), 6 (3.3%) to M. africanum West African 2 (MAF WA2,
Lineage 6), 3 (1.6%) to M. africanum West African 1 (MAF WA1,
Lineage 5), and 2 (1.1%) to the Central Asian (CAS, Lineage 3) lin-
eage. The largest families were the T (including the
T-sublineages: T1, T3, and T5) – and Haarlem (H1 and H3) – fam-
ilies, with 60 and 32 isolates, respectively, both members of the
Euro-American lineage. Other families include LAM, LAM10_CAM
(also called Cameroon family), X-clade and S-clade (all
Euro-American); Beijing (East Asian); Family34 and EAI (both
Indo-Oceanic); CAS (Central Asia); and MAF WA1&2 with different
proportions (Table 2).
In total, 132 (71.7%) MTBC isolates were genotypically clustered
(28 clusters containing 2–21 isolates per cluster). The two largest
clusters identiﬁed in the present study consisted of SIT53 isolates
(n = 21) of the T-family and SIT61 isolates (n = 12) of the
LAM10_CAM family. Other major genotypic clusters were charac-
terized by spoligotypes SIT50 (n = 9); SIT1/Beijing (n = 8); SIT46
(n = 8) and SIT465 (n = 7). Of note, 52 (28.3%) isolates were repre-
sented by a unique spoligotype-pattern only found once in the
study (Table S1).Table 2
Distribution of major M. tuberculosis complex families (lineages 1–6) from a
drug.
Lineage (L) Family
Indo-Oceanic (L1) Family34
EAI
East Asian (L2) Beijing
Central Asian (L3) CAS
Euro-American (L4) LAM
LAM10_CAM
Haarlem
T-clade
S-clade
X-clade
U-clade
West African 1 (L5) MAF WA1
West African 2 (L6) MAF WA2
Mycobacterium tuberculosis complex lineages and families from 184 (Oﬂotu
tuberculosis in Guinea. L = lineage, EAI = East-African Indian; CAS = Centr
American-Mediterranean10_Cameroon; MAF WA 1/2 =M. africanum West3.3. Detection of emerging spoligotypes (DESTUS analysis)
Based on the spoligotype data using the DESTUS model, SIT61 of
the LAM10_CAM family was detected to be spreading signiﬁcantly
faster (p < 0.001) than the background rate of the overall spoligo-
type population.3.4. Association of mycobacterial families and drug-resistance
The distribution of mycobacterial families among any resistant
isolates (43 isolates in total) showed a predominance of the
Euro-American lineage (Tables 2 and S1). Of the three MDR iso-
lates, two belonged to the T-family and one to the LAM-family
(Table S2). In the overall statistical comparison of the drug resis-
tance proﬁles, no signiﬁcant associations were found (data not
shown). However, in an exploratory analysis in which each family
was compared separately against the others, Beijing strains were
more likely to be poly-resistant (resistant to INH and SM but sus-
ceptible to RMP; OR = 5.61; 95%CI, 1.23–25.56; p = 0.013), the
T-family was associated with RMP resistance (OR = 11.18; 95%CI,
1.28–97.98; p = 0.007) and LAM10_CAM isolates were correlated
with mono-resistance to INH or SM (OR = 6.50; 95%CI, 1.89–
22.39; p = 0.001).4. Discussion
Several studies have reported the prevalence and distribution of
MTBC genotypes in other parts of the West African region
(Niobe-Eyangoh et al., 2003; Godreuil et al., 2007; Affolabi et al.,total of 184 strains and within family proportion of resistance to any
No. of total isolates (%) No. of resistant isolates
within each family (%)
14/184 (8%) –
5/184 (3%) 1/5 (20%)
8/184 (4%) 3/8 (37%)
2/184 (1%) –
23/184 (13%) 4/23 (17%)
13/184 (7%) 5/13 (38%)
32/184 (17%) 9/32 (28%)
60/184 (33%) 13/60 (22%)
4/184 (2%) 1/4 (25%)
6/184 (3%) –
8/184 (4%) 6/8 (75%)
3/184 (2%) –
6/184 (3%) 1/6 (17%)
b and Study C clinical trials) isolates of new patients with pulmonary
al Asian; LAM = Latin American-Mediterranean; LAM10_CAM = Latin
African 1/2.
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2011; Traore et al., 2012); however, very little is known about the
genotypic diversity of this pathogen in Guinea. This study reports
the ﬁrst use of genotyping and DST to assess the genetic diversity
and resistance proﬁles of MTBC strains circulating in Guinea.
In the combined analysis of the baseline DST results, MDR was
found in 2.5% of new pulmonary TB patients in Guinea, which is
similar to estimates from neighboring countries around the same
period; Guinea-Bissau (2.8%), Senegal (3.6%), Mali (2.2%), Côte
d’Ivoire (2.8%) and Sierra Leone (3.1%) (Ben Amor et al., 2008;
WHO, 2008); also results from other West African countries such
as The Gambia (0.5%) (Adegbola et al., 2003; WHO, 2008), Benin
(1%), Burkina Faso (2.9%), Ghana (2.2%) and Nigeria (2.3%) (Ben
Amor et al., 2008; WHO, 2008) are in concordance with our ﬁnding.
Moreover, like in other West African countries, there is consider-
able resistance to INH (17.5% of all strains) and/or SM (18.9% of
all strains), which patients may be at increased risk of amplifying
resistance. Other studies have shown various outcomes of INH
monoresistant TB. In low endemic countries, such as Denmark
and the US, treatment duration was typically modiﬁed when INH
resistance was detected, and outcome was good (Cattamanchi
et al., 2009; Bang et al., 2010). In TB endemic countries, such as
South Africa, outcome of INH resistance was worse (Jacobson
et al., 2011). In the context of an INH- and EMB based continuation
phase in use in Vietnam (Cattamanchi et al., 2009), INH resistance
was associated with an increased relapse rate. Should the high rate
of INH resistance be conﬁrmed in a drug resistance survey, the NTP
could consider the addition of EMB to the INH + RMP continuation
phase, as recommended by WHO, albeit based on weak evidence
(WHO, 2010). We found that most MTBC lineages were identiﬁed
in the present study, short of the recently identiﬁed lineage 7
(Firdessa et al., 2013) and Mycobacterium bovis or other animal
strains. The majority of strains belonged to the Euro-American lin-
eage 4, which is consistent with previous ﬁndings from neighbor-
ing countries such as Ivory Coast (Ouassa et al., 2012), Sierra Leone
(Homolka et al., 2008) and Guinea-Bissau (Groenheit et al., 2011)
as well as the Gambia (de Jong et al., 2009; Gehre et al., 2013).
Interestingly, Sierra Leone, Guinea-Bissau and Guinea have the
highest proportions (10–11%) of Indo-Oceanic strains (Lineage 1)
in West Africa (Homolka et al., 2008; Groenheit et al., 2011) the
reason of which is currently unknown. The wide spread of this
ancestral MTBC lineage may reﬂect the population mobility
between these neighboring countries, as currently exempliﬁed by
the Ebola epidemics. In contrast to previous reports that showed
that the two M. africanum clades were among the predominant
genotypes characteristic of the Western African region (de Jong
et al., 2010a,b), the present ﬁndings revealed a lower than
expected prevalence of 4.9% for bothM. africanum clades combined
in Guinea. Although surprising, this observation is in line with sev-
eral reports (de Jong et al., 2010a,b) that have shown decreasing
prevalence estimates of M. africanum during the last decades and
at various frequencies in Cameroon (Niobe-Eyangoh et al., 2003),
Burkina Faso (Godreuil et al., 2007) and in Guinea-Bissau
(Groenheit et al., 2011), and also Côte d’Ivoire reporting a low
prevalence (2%) of M. africanum (Ouassa et al., 2012). To date, the
factors that might contribute to the decline of M. africanum strains
in a particular population or region are poorly understood. It is
conceivable that M. africanum is more susceptible than M. tubercu-
losis to TB prevention and treatment measures currently in use
throughout West Africa. Previous studies from the Gambia, how-
ever, did not ﬁnd greater protection from M. bovis BCG against M.
africanum than M. tuberculosis (de Jong et al., 2010a,b).
Publications from Ghana (Yeboah-Manu et al., 2011) and Mali
(Traore et al., 2012) reported that M. africanum is less likely to be
resistant to ﬁrst line anti-tuberculosis drugs than M. tuberculosisclades, yet this does not explain a decrease in M. africanum preva-
lence, as transmission largely, if not exclusively, takes place before
the initiation of TB treatment.
The most frequent mycobacterial family identiﬁed was the
ill-deﬁned T-family within Lineage 4, accounting for almost
one-third of all isolates. This family was reportedly much less
frequent in other West African countries such as Burkina Faso
(Godreuil et al., 2007), Ghana (Yeboah-Manu et al., 2011),
Sierra Leone (Homolka et al., 2008), Benin (Affolabi et al.,
2009) and Nigeria (Ani et al., 2010) and therefore Guinea is the
West African country with the highest prevalences of the
T-clade, with SIT53 as the predominant T-family spoligotype.
Even though the ill-deﬁned T-superfamilies grouped under the
modern monophyletic Lineage 4 (Coscolla and Gagneux, 2014),
the sublineages of the T-family were shown to be a polyphyletic
clade (Demay et al., 2012), and did not represent a family in a
strict evolutionary sense (Brudey et al., 2006). Therefore future
phylogenetic SNP based studies need to be conducted to eluci-
date the detailed population structure within this family
(Stucki et al., 2012, 2014; Coscolla et al., 2015). Interestingly,
spoligotype SIT61, commonly known as LAM10-CAM given its
original description from Cameroon (Niobe-Eyangoh et al.,
2004), is also found in Guinea, and DESTUS analysis suggests that
these isolates are spreading faster than the background popula-
tion of all spoligotypes in our setting. Although the exact reason
for the observed emergence is elusive, a recent publication
demonstrated that certain genotypes within the LAM10-CAM
family were associated with HIV infections in Nigeria (Cadmus
et al., 2011) and therefore HIV infection as a risk factor for
increased transmission of these genotypes could be further
explored in our setting in future studies, as HIV data was not
consistently available within the parent studies. Moreover, our
ﬁndings suggest that the various mycobacterial families may dif-
fer quantitatively and qualitatively in their individual capacity of
developing drug-resistance. While Beijing strains were more fre-
quently poly-resistant, LAM10-CAM mostly resistant to INH and
SM, the T-family preferably developed RMP resistance. While an
association between HIV and drug resistance has been found in
some settings, yet not others (Sergeev et al., 2012), future studies
should include this and other host risk factors for developing
drug-resistance.
This study has limitations. We did not genotype all isolates from
Guinea in these studies, which may have introduced a selection
bias, although the selection was random and drug-resistance
proﬁles of the genotyped subset were comparable to the overall
bacterial population. Also, we did not correct for multiple testing,
and a potential weakness is that some of the associations we
identiﬁed on comparison per strain type may be spurious. Also a
potential misclassiﬁcation of LAM isolates as T strains, could
impact on the association studies. Therefore these results should
be considered exploratory, to be conﬁrmed by larger studies in
the same setting using higher resolution phylogenetic markers.
In conclusion, our ﬁndings suggest that the genotypic charac-
teristic of the MTBC population structure analyzed in Guinea was
diverse and all known MTBC lineages and families of human rele-
vance were identiﬁed in this study. Moreover, supplementary anal-
ysis revealed the association of some of MTBC families and
drug-resistance proﬁles. As mycobacterial population structures
are often geographically restricted, genetic characterization studies
to detect the presence of resistance-prone strains could be used to
forecast drug-resistance proﬁles in a country. Therefore, our ﬁnd-
ings provide a ﬁrst insight into the genotypes, population structure
of MTBC, and prevalence of drug resistance in the area, contribut-
ing information for scientists as well as public health researchers in
tuberculosis control programmes.
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